New vaccine for the prevention of Chikungunya
Chikungunya is a viral disease transmitted to humans by infected mosquitoes and is characterised by abrupt onset of fever with debilitating joint pain.
Unique selling point/competitive advantage
Currently, there is no cure or approved vaccine for prevention of Chikungunya. This new vaccine could help in preventing Chikungunya infection. It may also provide protection against other similar viruses.
Investment or collaboration opportunities
Griffith University is seeking to partner with a company that can further develop and bring this vaccine to market.
Griffith University is offering an exclusive licence to the intellectual property, know-how and materials, and access to their team for further joint research and development (R&D) and consultancy.
Intellectual property rights
Griffith University has full rights to this technology.
Phone: +61 7 5678 7536
- Learn about Professor Suresh Mahalingam, the principal research leader for this vaccine.
- Visit Griffith Enterprise for more information.
- Last reviewed: 17 Jul 2019
- Last updated: 30 May 2018